{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:29:06Z","timestamp":1792348146454,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40121-024-00939-w","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T10:03:37Z","timestamp":1710929017000},"page":"827-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-3812","authenticated-orcid":false,"given":"Daniel","family":"Molnar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-8961","authenticated-orcid":false,"given":"Elizabeth M.","family":"La","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8399-743X","authenticated-orcid":false,"given":"Frederik","family":"Verelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-057X","authenticated-orcid":false,"given":"Sara","family":"Poston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3227-5928","authenticated-orcid":false,"given":"Jonathan","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2641-6787","authenticated-orcid":false,"given":"Laure-Anne","family":"Van Bellinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-0111","authenticated-orcid":false,"given":"Desmond","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"issue":"10","key":"939_CR1","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/thoraxjnl-2018-212212","volume":"74","author":"JA Coultas","year":"2019","unstructured":"Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax. 2019;74(10):986\u201393. https:\/\/doi.org\/10.1136\/thoraxjnl-2018-212212.","journal-title":"Thorax"},{"issue":"17","key":"939_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa043951","volume":"352","author":"AR Falsey","year":"2005","unstructured":"Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749\u201359. https:\/\/doi.org\/10.1056\/NEJMoa043951.","journal-title":"N Engl J Med"},{"key":"939_CR3","doi-asserted-by":"publisher","first-page":"204993612210914","DOI":"10.1177\/20499361221091413","volume":"9","author":"DH Villanueva","year":"2022","unstructured":"Villanueva DH, Arcega V, Rao M. Review of respiratory syncytial virus infection among older adults and transplant recipients. Ther Adv Infect Dis. 2022;9:20499361221091412. https:\/\/doi.org\/10.1177\/20499361221091413.","journal-title":"Ther Adv Infect Dis"},{"key":"939_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5021","volume":"366","author":"HH Nam","year":"2019","unstructured":"Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366: l5021. https:\/\/doi.org\/10.1136\/bmj.l5021.","journal-title":"BMJ"},{"issue":"2","key":"939_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0527","volume":"5","author":"CL Hansen","year":"2022","unstructured":"Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and respiratory syncytial virus in the US, 1999\u20132018. JAMA Netw Open. 2022;5(2): e220527. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0527.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"939_CR6","doi-asserted-by":"publisher","first-page":"ofac300","DOI":"10.1093\/ofid\/ofac300","volume":"9","author":"JM McLaughlin","year":"2022","unstructured":"McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac300. https:\/\/doi.org\/10.1093\/ofid\/ofac300.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"939_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/infdis\/jiaa361","volume":"222","author":"HF Tseng","year":"2020","unstructured":"Tseng HF, Sy LS, Ackerson B, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis. 2020;222(8):1298\u2013310. https:\/\/doi.org\/10.1093\/infdis\/jiaa361.","journal-title":"J Infect Dis"},{"key":"939_CR8","unstructured":"Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus infection (RSV). https:\/\/www.cdc.gov\/rsv\/index.html. Accessed 24 Oct 2022."},{"key":"939_CR9","unstructured":"Centers for Disease Control and Prevention (CDC). RSV in older adults and adults with chronic medical conditions. https:\/\/www.cdc.gov\/rsv\/high-risk\/older-adults.html. Accessed 6 Jan 2022."},{"issue":"1","key":"939_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1413456","volume":"374","author":"HC Meissner","year":"2016","unstructured":"Meissner HC. Viral bronchiolitis in children. N Engl J Med. 2016;374(1):62\u201372. https:\/\/doi.org\/10.1056\/NEJMra1413456.","journal-title":"N Engl J Med"},{"issue":"2","key":"939_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/ciy991","volume":"69","author":"B Ackerson","year":"2019","unstructured":"Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197\u2013203. https:\/\/doi.org\/10.1093\/cid\/ciy991.","journal-title":"Clin Infect Dis"},{"issue":"40","key":"939_CR12","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.15585\/mmwr.mm7240a2","volume":"72","author":"D Surie","year":"2023","unstructured":"Surie D, Yuengling KA, DeCuir J, et al. Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged \u2265 60 years - IVY network, 20 US States, February 2022\u2013May 2023. MMWR Morb Mortal Wkly Rep. 2023;72(40):1083\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7240a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"939_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/irv.13043","volume":"16","author":"AR Branche","year":"2022","unstructured":"Branche AR, Saiman L, Walsh EE, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Influenza Other Respir Viruses. 2022;16(6):1151\u201360. https:\/\/doi.org\/10.1111\/irv.13043.","journal-title":"Influenza Other Respir Viruses"},{"key":"939_CR14","unstructured":"US Food & Drug Administration (FDA). AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted). https:\/\/www.fda.gov\/media\/167805\/download. Accessed 29 Sept 2023."},{"key":"939_CR15","unstructured":"US Food & Drug Administration (FDA). ABRYSVO (Respiratory Syncytial Virus Vaccine). https:\/\/www.fda.gov\/media\/168889\/download. Accessed 29 Sept 2023."},{"issue":"7","key":"939_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2209604.","journal-title":"N Engl J Med"},{"issue":"16","key":"939_CR17","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, Perez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465\u201377. https:\/\/doi.org\/10.1056\/NEJMoa2213836.","journal-title":"N Engl J Med"},{"issue":"1","key":"939_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C, Garcon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16(1):55\u201363. https:\/\/doi.org\/10.1080\/14760584.2016.1213632.","journal-title":"Expert Rev Vaccines"},{"issue":"29","key":"939_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","volume":"72","author":"M Melgar","year":"2023","unstructured":"Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793\u2013801. https:\/\/doi.org\/10.15585\/mmwr.mm7229a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"939_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae010","author":"MG Ison","year":"2024","unstructured":"Ison MG, Papi A, Athan E, et al. Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae010.","journal-title":"Clin Infect Dis"},{"key":"939_CR21","unstructured":"US Census Bureau. Projected Population by Single Year of Age, Sex, Race, and Hispanic Origin for the United States: 2016 to 2060. 2018. https:\/\/www.census.gov\/data\/datasets\/2017\/demo\/popproj\/2017-popproj.html. Accessed 10 Mar 2022."},{"issue":"2","key":"939_CR22","first-page":"1","volume":"71","author":"E Arias","year":"2022","unstructured":"Arias E, Xu J, Tejada-Vera B, Murphy SL, Bastian B. US State life tables, 2020. Natl Vital Stat Rep. 2022;71(2):1\u201318.","journal-title":"Natl Vital Stat Rep"},{"issue":"7","key":"939_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa1315727","volume":"371","author":"CA DiazGranados","year":"2014","unstructured":"DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635\u201345. https:\/\/doi.org\/10.1056\/NEJMoa1315727.","journal-title":"N Engl J Med"},{"issue":"8","key":"939_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182321","volume":"12","author":"AD Colosia","year":"2017","unstructured":"Colosia AD, Yang J, Hillson E, et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS ONE. 2017;12(8): e0182321. https:\/\/doi.org\/10.1371\/journal.pone.0182321.","journal-title":"PLoS ONE"},{"key":"939_CR25","unstructured":"Centers for Disease Control and Prevention (CDC). National respiratory and enteric virus surveillance system (NREVSS). https:\/\/www.cdc.gov\/surveillance\/nrevss\/. Accessed 22 Oct 2022."},{"issue":"3","key":"939_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.vaccine.2021.12.002","volume":"40","author":"WL Herring","year":"2022","unstructured":"Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022;40(3):483\u201393. https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.002.","journal-title":"Vaccine"},{"issue":"12","key":"939_CR27","doi-asserted-by":"publisher","first-page":"ofy316","DOI":"10.1093\/ofid\/ofy316","volume":"5","author":"EA Belongia","year":"2018","unstructured":"Belongia EA, King JP, Kieke BA, et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults \u2265 60 years old. Open Forum Infect Dis. 2018;5(12):ofy316. https:\/\/doi.org\/10.1093\/ofid\/ofy316.","journal-title":"Open Forum Infect Dis"},{"key":"939_CR28","unstructured":"Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage for persons 6 months and older. 2022. https:\/\/www.cdc.gov\/flu\/fluvaxview\/interactive-general-population.htm. Accessed 12 Oct 2022."},{"issue":"3","key":"939_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/cid\/ciad161","volume":"77","author":"T Van Effelterre","year":"2023","unstructured":"Van Effelterre T, Hens N, White LJ, et al. Modeling respiratory syncytial virus adult vaccination in the United States with a dynamic transmission model. Clin Infect Dis. 2023;77(3):480\u20139. https:\/\/doi.org\/10.1093\/cid\/ciad161.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"939_CR30","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/ciab595","volume":"74","author":"AR Branche","year":"2022","unstructured":"Branche AR, Saiman L, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017\u20132020. Clin Infect Dis. 2022;74(6):1004\u201311. https:\/\/doi.org\/10.1093\/cid\/ciab595.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"939_CR31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/irv.12929","volume":"16","author":"D Curran","year":"2022","unstructured":"Curran D, Cabrera ES, Bracke B, et al. Impact of respiratory syncytial virus disease on quality of life in adults aged \u2265 50 years: a qualitative patient experience cross-sectional study. Influenza Other Respir Viruses. 2022;16(3):462\u201373. https:\/\/doi.org\/10.1111\/irv.12929.","journal-title":"Influenza Other Respir Viruses"},{"issue":"10325","key":"939_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"issue":"7","key":"939_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-011341","volume":"8","author":"C Kim","year":"2023","unstructured":"Kim C, Holm M, Frost I, Hasso-Agopsowicz M, Abbas K. Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study. BMJ Glob Health. 2023;8(7): e011341. https:\/\/doi.org\/10.1136\/bmjgh-2022-011341.","journal-title":"BMJ Glob Health"},{"key":"939_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad658","author":"SM Moghadas","year":"2023","unstructured":"Moghadas SM, Shoukat A, Bawden CE, et al. Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciad658.","journal-title":"Clin Infect Dis"},{"key":"939_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad471","author":"RG Feldman","year":"2023","unstructured":"Feldman RG, Antonelli-Incalzi R, Steenackers K, et al. Respiratory syncytial virus prefusion F protein vaccine is efficacious in older adults with underlying medical conditions. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciad471.","journal-title":"Clin Infect Dis"},{"key":"939_CR36","unstructured":"Curran C, Matthews S, Sabater E, et al. The respiratory syncytial virus prefusion F protein candidate vaccine (RSVPreF3 OA) attenuates the severity of RSV in breakthrough infections in adults \u2265 60 years of age. Presented at the 7th ReSViNET Conference (RSVVW'23); 22\u201324, 2023. Lisbon, Portugal."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00939-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:25:36Z","timestamp":1714397136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00939-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00939-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, and Desmond Curran are employees of GSK and hold shares in GSK. Jonathan Graham is an employee of RTI Health Solutions, which received consultancy fees from GSK to complete the work disclosed here and for other projects unrelated to the submitted work. Laure-Anne Van Bellinghen is an employee of CHESS in Health, which received funding from GSK to complete the work disclosed here and for additional projects unrelated to the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This analysis is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Ethical approval for the development of the model was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}